5-YEAR OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA BY LINE OF TREATMENT FROM THE FRENCH HEMATOLOGIC MALIGNANCY REGISTRY

被引：1
|
作者：
Mounier, M. [1 ]
Gauthier, S. [1 ]
Mayandi [2 ]
Troussard, X. [3 ]
Monnereau, A. [4 ]
Guilhaume, C. [5 ]
Suzan, F. [6 ]
Blachier-Poisson, C. [5 ]
Despiegel, N. [5 ]
机构：
[1] Univ Bourgogne, Dijon, France
[2] Ctr Hosp Univ Dijon, Dijon, France
[3] CHU Caen, Caen, France
[4] Inst Bergonie, Bordeaux, France
[5] Amgen France, Paris, France
[6] Amgen Europe GmbH, Zug, Switzerland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2374
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN297
引用
收藏
页码：A762 / A762
页数：1
相关论文
共 50 条
  • [1] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    [J]. BLOOD, 2023, 142
  • [2] Soluble MICA as a prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, V.
    Schuett, P.
    Brandhorst, D.
    Opalka, B.
    Nowrousian, M. R.
    Moritz, T.
    Grosse-Wilde, H.
    [J]. TISSUE ANTIGENS, 2007, 69 (05): : 390 - 390
  • [3] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [4] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [5] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
  • [6] Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, Vera
    Schuett, Philipp
    Brandhorst, Dieter
    Opalka, Bertram
    Moritz, Thomas
    Nowrousian, Mohammad Reza
    Grosse-Wilde, Hans
    [J]. CLINICAL IMMUNOLOGY, 2007, 123 (01) : 114 - 120
  • [7] Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Tay, Jason
    Bahlis, Nizar J.
    [J]. BLOOD, 2016, 128 (22)
  • [8] Impact of interferon maintenance therapy on multiple myeloma patients' quality of life, progression-free survival and overall survival
    Bumeder, I
    Tyroller, M.
    Fischer, N.
    Busch, R.
    Frick, E.
    [J]. PSYCHO-ONCOLOGY, 2006, 15 (02) : S187 - S188
  • [9] Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
    Ludwig, Heinz
    Adam, Zdenek
    Tothova, Elena
    Hajek, Roman
    Labar, Boris
    Egyed, Miklos
    Spicka, Ivan
    Gisslinger, Heinz
    Drach, Johannes
    Kuhn, Ingrid
    Hinke, Axel
    Zojer, Niklas
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09): : 1548 - 1554
  • [10] Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint
    Rosenberg, Aaron Seth
    Facon, Thierry
    Abouzaid, Safiya
    Srinivasan, Shankar
    Chung, Weiyuan
    Parikh, Kejal
    Tuscano, Joseph
    [J]. BLOOD, 2017, 130
12345